Open Orphan, Immotion and Pires Investments
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Open Orphan, Immotion and Pires Investments
Cathal Friel, Chief Executive Officer of Open Orphan (ORPH) explains how they are targeting profitable growth and a return to profitability in 2020.
Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services business. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.
Martin Higginson, Chief Executive Officer of Immotion (IMMO) covers the highlights from their interim results and current progress which hopes to see them reaching monthly breakeven in Q1 2020.
Immotion Group aims to become a market leader in the western market sector of the “Out of Home” virtual reality market, through its “Create, Publish and Distribute” model, with the objective of creating recurring revenues from a large installed base of Virtual Reality (“VR”) Motion Platforms.
(Interview starts at 12 minutes 30 seconds)
Nick Lee Non-Executive of Pires Investments (PIRI) covers their recent update and explain why they hope to amend their investment strategy.
Pires invests in companies that have the potential for major transformation and exponential growth.
(Interview starts at 20 minutes 8 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.